Pharma/Fine Chemicals Roundup – September 18
9:19 AM MDT | September 18, 2012 | By DEEPTI RAMESH
IMCD ACQUIRES PHARMA INGREDIENTS DISTRIBUTOR IN MALAYSIA
Distributor IMCD Group (Rotterdam), says it has acquired the pharmaceutical ingredients distribution business of Maxwell Pharma (Petaling Jaya, Malaysia), a privately owned company. Financial details were not disclosed. Maxwell, which was established in 2000, is a distributor of active pharmaceutical ingredients (APIs) and excipients, and the company also has businesses in clinical studies and skin care products. The two companies are currently working closely to ensure smooth transition and the acquisition process will be closed on September 30, 2012, IMCD says.
INDIA TO SET UP NEW BODY TO CHECK QUALITY OF APIS EXPORTED TO EUROPE
The Indian government will set up an authority by the end of this month to certify the quality of active pharmaceutical ingredients (APIs) that are meant for exports to Europe, say press reports. Countries exporting APIs to Europe are expected to comply with new European Union (EU) norms for APIs, by July 2013. APIs manufactured outside Europe for export to EU countries will have comply with EU cGMP standards, and the compliance will have to be confirmed by the authority of the exporting country, reports say.
PFIZER AND HISUN LAUNCH $545-MILLION GENERICS JV IN CHINA
Pfizer and Zhejiang Hisun Pharmaceutical (Taizhou, China), a leading pharmaceutical company in China, have launched Hisun-Pfizer Pharmaceuticals, a previously announced joint venture in China between the two companies to develop, manufacture, and commercialize off-patent pharmaceutical products in China and global markets. Hisun-Pfizer has an aggregate investment of $295 million and a registered capital of $250 million. Hisun holds 51%-stake in the jv and Pfizer holds the remaining 49%. The registration facilities and production plants of the jv will be located at Fuyang, Zhejiang Province, while the management center and R&D center will be located at Shanghai and Hangzhou, respectively. Off-patent medicines, including branded generics, represent one of the fastest-growing segments in the global pharmaceutical market, Pfizer says. In China, branded generics account for 70% of the domestic pharmaceutical market, Pfizer says.
BAYER TO ACQUIRE TEVA’S U.S. ANIMAL HEALTH BUSINESS FOR $145 MILLION
Bayer and Teva Pharmaceutical Industries (Petach Tikva, Israel) say that Bayer HealthCare has signed an agreement to acquire Teva's U.S. animal health business for up to $145 million. The purchase price includes an up-front payment of $60 million and a total of $85 million in milestone payments, which are linked to the successful and timely achievement of manufacturing and sales targets. The acquisition will reinforce the food animal franchise of Bayer HealthCare by providing a range of anti-infective solutions for livestock and by introducing reproductive hormones to Bayer’s product offerings, Bayer says. It will also strengthen Bayer HealthCare’s companion animal franchise by expanding its portfolio with dermatological, pet wellness, and nutraceutical products. The acquisition, which includes a manufacturing site at St. Joseph, MO, and about 300 employees, is expected to be completed in 2013, Bayer says.
BASF CELEBRATES 20-YEAR ANNIVERSARY OF IBUPROFEN API PLANT IN U.S.
BASF, which is one of the leading producers of generic active pharmaceutical ingredients (APIs), recently celebrated twenty years of operations in the manufacturing of ibuprofen API at the company’s Bishop, TX, site. BASF's Bishop site manufactures ibuprofen, a commonly used pain-killer drug substance, deploying an environmentally friendly production technique that avoids the use of chromium salts and minimizes waste. The Bishop facility began operations in September 1992. Since then, it has become one of the world’s most significant ibuprofen plants, BASF says. For more than 75 years, BASF has been a leading supplier of generic active ingredients such as ibuprofen, theophylline, pseudoephedrine, and caffeine to the pharmaceutical industry, the company says. In 2013, BASF will extend its portfolio by introducing a pharmaceutical grade of L-menthol to the market.
RANBAXY TO BUILD PRODUCTION FACILITY IN MALAYSIA
Indian pharmaceutical major Ranbaxy Laboratories (Gurgaon, India) says its Ranbaxy Malaysia (Kuala Lumpur) subsidiary has received approval from the Malaysian government to build a greenfield manufacturing facility in Malaysia. Ranbaxy will invest about $40 million in the project. It will be Ranbaxy's second manufacturing facility in Malaysia. The new facility will manufacture dosage forms primarily in the cardiovascular, antidiabetic, anti-infective and gastrointestinal segments. “In addition to serving the local market, the facility will also export products to markets like Asean, Mideast, Europe, Sri Lanka, China, and other select countries,” says Arun Sawhney, CEO and managing director of Ranbaxy. Ranbaxy Malaysia’s existing manufacturing facility is located at Sungai Petani.